Browsing by Author "Calon, Alexandre"

Sort by: Order: Results:

  • Challenges and therapeutic opportunities in the dMMR/MSI-H colorectal cancer landscape
    Mulet Margalef, Núria; Linares Aceituno, Jenniffer Lissethe; Badia-Ramentol, Jordi; Jimeno, Mireya; Sanz Monte, Carolina; Manzano Mozo, José Luis; Calon, Alexandre (MDPI, 2023)
    About 5 to 15% of all colorectal cancers harbor mismatch repair deficient/microsatellite instability–high status (dMMR/MSI-H) that associates with high tumor mutation burden and increased immunogenicity. As a result, and ...
  • Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia
    Blanco Ares, Gonzalo, 1989-; Puiggros Metje, Anna Maria; Sherry, Barbara; Nonell Mazelon, Lara, 1972-; Calvo Gonzalo, Xavier; Puigdecanet Riubugent, Eulàlia; Arnal, Magdalena; Rodríguez-Rivera, María; Gimeno Vázquez, Eva; Abella Monreal, Eugenia; Calon, Alexandre; Ferrer Del Alamo, Ana; Espinet Solà, Blanca (Elsevier, 2021)
    Several studies in chronic lymphocytic leukemia (CLL) patients have reported impaired immune cell functions, which contribute to tumor evasion and disease progression. However, studies on CLL-like monoclonal B-cell ...
  • Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer
    Tarazona, Noelia; Calon, Alexandre; Cervantes, Andrés (Elsevier, 2020)
    Background: Colon cancer (CC) is a heterogeneous disease. Novel prognostic factors beyond pathological staging are required to accurately identify patients at higher risk of relapse. Integrating these new biological factors, ...
  • Determinants and functions of CAFs secretome during cancer progression and therapy
    Linares Aceituno, Jenniffer Lissethe; Marín Jiménez, Juan A.; Badia-Ramentol, Jordi; Calon, Alexandre (Frontiers, 2021)
    Multiple lines of evidence are indicating that cancer development and malignant progression are not exclusively epithelial cancer cell-autonomous processes but may also depend on crosstalk with the surrounding tumor ...
  • Determinants of metastatic competency in colorectal cancer
    Tauriello, Daniele V.F.; Calon, Alexandre; Lonardo, Enza; Batlle Gómez, Eduard (Wiley, 2017)
    Colorectal cancer (CRC) is one of the most common cancer types and represents a major therapeutic challenge. Although initial events in colorectal carcinogenesis are relatively well characterized and treatment for early-stage ...
  • Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy
    Linares Aceituno, Jenniffer Lissethe; Sallent-Aragay, Anna; Badia-Ramentol, Jordi; Recort-Bascuas, Alba; Manero Rupérez, Noemí; Rivas, Elisa; Zwick, Melissa; Iglesias Coma, Mar; Orrillo, Mayra; Garrido, Marta; Navarro Medrano, Pilar; Montagut Viladot, Clara; Calon, Alexandre (Nature Research, 2023)
    A substantial proportion of cancer patients do not benefit from platinum-based chemotherapy (CT) due to the emergence of drug resistance. Here, we apply elemental imaging to the mapping of CT biodistribution after therapy ...
  • Minimal residual disease, metastasis and immunity
    Badia-Ramentol, Jordi; Linares Aceituno, Jenniffer Lissethe; Gómez-Llonín, Andrea; Calon, Alexandre (MDPI, 2021)
    Progression from localized to metastatic disease requires cancer cells spreading to distant organs through the bloodstream. Only a small proportion of these circulating tumor cells (CTCs) survives dissemination due to ...
  • Peptide-platinum(IV) conjugation minimizes the negative impact of current anticancer chemotherapy on nonmalignant cells
    Linares Aceituno, Jenniffer Lissethe; Varese, Monica; Sallent-Aragay, Anna; Méndez, Ana; Palomo-Ponce, Sergio; Iglesias Coma, Mar; Batlle Gómez, Eduard; Pisonero, Jorge; Montagut Viladot, Clara; Giralt, Ernest; Lo Re, Daniele; Calon, Alexandre (American Chemical Society (ACS), 2023)
    The relative success of platinum (Pt)-based chemotherapy comes at the cost of severe adverse side effects and is associated with a high risk of pro-oncogenic activation in the tumor microenvironment. Here, we report the ...
  • Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
    Calon, Alexandre; Lonardo, Enza; Berenguer-Llergo, Antonio; Espinet, Elisa; Hernando-Momblona, Xavier; Iglesias Coma, Mar; Sevillano, Marta; Palomo-Ponce, Sergio; Tauriello, Daniele V.F.; Byrom, Daniel; Cortina Duran, Carme; Morral Martínez, Clara, 1989-; Barceló, Carles; Tosi, Sebastien; Riera, Antoni; Attolini, Camille Stephan-Otto; Rossell, David; Sancho, Elena; Batlle Gómez, Eduard (Nature Publishing Group, 2015)
    Recent molecular classifications of colorectal cancer (CRC) based on global gene expression profiles have defined subtypes displaying resistance to therapy and poor prognosis. Upon evaluation of these classification systems, ...
  • Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
    Rivas, Elisa; Linares Aceituno, Jenniffer Lissethe; Zwick, Melissa; Gómez-Llonín, Andrea; Guiu, Marc; Labernadie, Anna; Badia-Ramentol, Jordi; Lladó, Anna; Bardia, Lídia; Pérez-Núñez, Iván; Martínez-Ciarpaglini, Carolina; Tarazona, Noelia; Sallent-Aragay, Anna; Garrido, Marta; Celià-Terrassa, Toni; Burgués, Octavio; Gomis, Roger R.; Albanell Mestres, Joan; Calon, Alexandre (Nature Research, 2022)
    About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment. Here, we conduct a detailed analysis of two ...
  • The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice
    Badia-Ramentol, Jordi; Gimeno-Valiente, Francisco; Duréndez, Elena; Martínez-Ciarpaglini, Carolina; Linares Aceituno, Jenniffer Lissethe; Iglesias Coma, Mar; Cervantes, Andrés; Calon, Alexandre; Tarazona, Noelia (Elsevier, 2023)
    Adjuvant chemotherapy following surgical intervention remains the primary treatment option for patients with localized colorectal cancer (CRC). However, a significant proportion of patients will have an unfavorable outcome ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking